Literature DB >> 2571297

Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by fenoldopam mesylate and dopamine in the rat.

W D Kerns1, E Arena, D G Morgan.   

Abstract

Fenoldopam mesylate (FM), a selective, postjunctional, dopaminergic (DA1) vasodilator, causes a novel lesion of large caliber splanchnic arteries (100 to 800 microns) in the rat characterized by necrosis of medial smooth muscle cells and hemorrhage. FM does not induce lesions in other vascular beds of the rat or in dogs or monkeys. Dopamine, like FM, causes hemorrhagic lesions of large caliber splanchnic arteries in the rat, as well as fibrinoid necrosis of small caliber arteries (less than 100 microns) of the splanchnic, cerebral, coronary, and renal vascular beds. Dopamine, an alpha- and beta-adrenoceptor and dopaminergic agonist, is used clinically, principally as a pressor agent. Because these arterial lesions were believed to result from the pharmacologic activity of these two compounds, the role of vascular receptor subtypes in their pathogenesis was investigated. Rats were coexposed to either FM or dopamine and a variety of receptor antagonists (alpha, beta, DA1, DA2, and 5HT2). In rats coexposed to the alpha-adrenoreceptor antagonist phenoxybenzamine (PBZ) and either FM or dopamine, the incidence and severity of hemorrhagic lesions of large caliber arteries were increased; PBZ, however, prevented the formation of dopamine-induced fibrinoid lesions in arteries of small caliber. SK&F 83566-C, a selective DA1 dopaminergic receptor antagonist, prevented the induction of FM and dopamine-induced hemorrhagic lesions of large caliber arteries. Rats exposed concurrently to dopamine, phenoxybenzamine, and SK&F 83566-C were free of all arterial lesions. The other receptor antagonists tested did not prevent arterial injury. Thus, the induction of splanchnic arterial lesions in the rat by dopamine and FM is caused by stimulation of, and interaction between, alpha-adrenoceptors and dopaminergic DA1 receptors. Activation of the postjunctional, dopaminergic (DA1) receptor is causally associated with the induction of novel hemorrhagic lesions of large caliber splanchnic arteries in the rat.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571297      PMCID: PMC1879911     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

1.  Arterial necrosis in the rat produced by methoxamine.

Authors:  B M HERBERTSON; T D KELLAWAY
Journal:  J Pathol Bacteriol       Date:  1960-07

2.  The DA1 receptor agonist fenoldopam (SK & F 82526) is also an alpha 2-adrenoceptor antagonist.

Authors:  E H Ohlstein; B Zabko-Potapovich; B A Berkowitz
Journal:  Eur J Pharmacol       Date:  1985-12-03       Impact factor: 4.432

Review 3.  The vascular dopamine receptor : a review.

Authors:  M Schmidt; J L Imbs; J Schwartz
Journal:  J Pharmacol       Date:  1981 Nov-Dec

4.  Medial changes in arterial spasm induced by L-norepinephrine.

Authors:  I Joris; G Majno
Journal:  Am J Pathol       Date:  1981-12       Impact factor: 4.307

5.  Acute and subchronic toxicology of LY-195115 in rats and dogs.

Authors:  G E Sandusky; J R Means
Journal:  Toxicol Lett       Date:  1987-09       Impact factor: 4.372

6.  Adrenoreceptor blockade in angiotensin-induced hypertension: effect on rat coronary arteries and myocardium.

Authors:  R D Bhan; F Giacomelli; J Wiener
Journal:  Am J Pathol       Date:  1982-07       Impact factor: 4.307

7.  Cardiovascular lesions in Sprague-Dawley rats induced by long-term treatment with caffeine.

Authors:  S Johansson
Journal:  Acta Pathol Microbiol Scand A       Date:  1981-05

Review 8.  Potential use of DA1 and DA2 receptor agonists in the treatment of hypertension.

Authors:  L I Goldberg; M B Murphy
Journal:  Clin Exp Hypertens A       Date:  1987

9.  Syntheses and in vitro evaluation of 4-(2-aminoethyl)-2(3H)-indolones and related compounds as peripheral prejunctional dopamine receptor agonists.

Authors:  R M DeMarinis; G Gallagher; R F Hall; R G Franz; C Webster; W F Huffman; M S Schwartz; C Kaiser; S T Ross; J W Wilson
Journal:  J Med Chem       Date:  1986-06       Impact factor: 7.446

10.  The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro.

Authors:  A Hughes; S Thom; G Martin; D Redman; S Hasan; P Sever
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

View more
  8 in total

1.  Pathologic observations in human allograft recipients treated with FK 506.

Authors:  A J Demetris; J J Fung; S Todo; B Banner; T Zerbe; G Sysyn; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  A bilayer small diameter in vitro vascular model for evaluation of drug induced vascular injury.

Authors:  David M Hoganson; Eric B Finkelstein; Gwen E Owens; James C Hsiao; Kurt Y Eng; Katherine M Kulig; Ernest S Kim; Tatiana Kniazeva; Irina Pomerantseva; Craig M Neville; James R Turk; Bernard Fermini; Jeffrey T Borenstein; Joseph P Vacanti
Journal:  Biomicrofluidics       Date:  2016-10-12       Impact factor: 2.800

3.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

4.  Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy.

Authors:  P S Randhawa; A C Tsamandas; M Magnone; M Jordan; R Shapiro; T E Starzl; A J Demetris
Journal:  Am J Surg Pathol       Date:  1996-03       Impact factor: 6.394

5.  Proceedings of the 2014 National Toxicology Program Satellite Symposium.

Authors:  Susan A Elmore; Michelle C Cora; Margarita M Gruebbel; Schantel A Hayes; Jessica S Hoane; Haruko Koizumi; Rachel Peters; Thomas J Rosol; Bhanu P Singh; Kathleen A Szabo
Journal:  Toxicol Pathol       Date:  2014-11-09       Impact factor: 1.902

6.  Characterization of the arteritis induced by infusion of rats with UK-61,260, an inodilator, for 24 h. A comparison with the arteritis induced by fenoldopam mesylate.

Authors:  G Hanton; J L Le Net; B Ruty; B Leblanc
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

7.  Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury.

Authors:  David A Brott; Anne Katein; Heath Thomas; Michael Lawton; Robert R Montgomery; Rudy J Richardson; Calvert S Louden
Journal:  Toxicol Pathol       Date:  2014-02-04       Impact factor: 1.902

8.  Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings.

Authors:  Robert A Ettlin; Junji Kuroda; Stephanie Plassmann; David E Prentice
Journal:  J Toxicol Pathol       Date:  2010-12-16       Impact factor: 1.628

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.